Over 500 million people worldwide suffer from diabetes—a disease that contributes to major complications such as stroke, ...

Post hoc results support the initiation of SGLT2 inhibitors in patients with diabetic nephropathy regardless of iron deficiency. Canagliflozin treatment may improve iron markers and hemoglobin levels ...